Tech Company Financing Transactions
Replicate Bioscience Funding Round
Replicate Bioscience closed a $40 million Series A funding round on 9/9/2021. Backers included Apple Tree Partners.
Transaction Overview
Company Name
Announced On
9/9/2021
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10210 Campus Point Dr. 150
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
Designing and delivering srRNA immunotherapies to revolutionize the practice of medicine and improve and save lives. We are applying advanced srRNA technology towards solving a life-threatening problem--drug resistance in cancers--using our proprietary synthetic immune lethality approach.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nathaniel Wang
Chief Scientific Officer
Michael Ehlers
VP - Bus. Development
Andrew Geall
Browse more venture capital transactions:
Prev: 9/9/2021: Attralus venture capital transaction
Next: 9/9/2021: PredictionStrike venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs